TITLE

Gatifloxacin in combination with rifampicin in a murine tuberculosis model

AUTHOR(S)
Michael Cynamon; Mary R. Sklaney; Carolyn Shoen
PUB. DATE
August 2007
SOURCE
Journal of Antimicrobial Chemotherapy (JAC);Aug2007, Vol. 60 Issue 2, p429
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Objectives Gatifloxacin previously demonstrated good in vitro and in vivo activities against Mycobacterium tuberculosis. Several regimens of gatifloxacin in combination with rifampicin were compared with isoniazid plus rifampicin in a mouse tuberculosis model. Methods C57BL/6 mice were infected intranasally with ∼106 viable M. tuberculosis organisms. Treatment with various regimens of gatifloxacin plus rifampicin was started 1 week post-infection and was administered for 4–12 weeks. Mice were euthanized at the end of therapy and their right lungs were removed and cell counts were determined. Results Gatifloxacin 100 mg/kg plus rifampicin 10 mg/kg has activity similar to that of isoniazid plus rifampicin in the 12 week treatment model. Gatifloxacin 300 mg/kg plus rifampicin 20 mg/kg yields a non-cultivatable state after 12 weeks of therapy and approaches but does not achieve a durable cure. Conclusions Gatifloxacin in combination with rifampicin is a promising combination for potential evaluation in human clinical trials. Gatifloxacin plus rifampicin regimens had activities similar to or better than isoniazid plus rifampicin. A quinolone plus rifampicin combination may provide the foundation for shorter course regimens than the current isoniazid plus rifampicin-based regimen.
ACCESSION #
25856713

 

Related Articles

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics